Takeda Pharmaceutical Company Ltd
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
Long-term Study of Alogliptin as an Add-on to Rapid-Acting Insulin Secretagogues in Type 2 Diabetes
Phase 3
Completed
- Conditions
- Diabetes Mellitus
- Interventions
- Drug: Rapid-acting insulin secretagogue
- First Posted Date
- 2011-10-20
- Last Posted Date
- 2014-04-21
- Lead Sponsor
- Takeda
- Target Recruit Count
- 67
- Registration Number
- NCT01456130
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
- First Posted Date
- 2011-10-20
- Last Posted Date
- 2016-04-05
- Lead Sponsor
- Takeda
- Target Recruit Count
- 421
- Registration Number
- NCT01456195
Study to Assess the Effects of Daily Administration of Pioglitazone on Brain Hemodynamics in Healthy Elderly Participants
- First Posted Date
- 2011-10-20
- Last Posted Date
- 2012-08-08
- Lead Sponsor
- Takeda
- Target Recruit Count
- 61
- Registration Number
- NCT01456117
A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone
Phase 3
Completed
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2011-10-20
- Last Posted Date
- 2014-04-23
- Lead Sponsor
- Takeda
- Target Recruit Count
- 507
- Registration Number
- NCT01456169
Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)
Phase 3
Completed
- Conditions
- Gastric UlcersDuodenal Ulcers
- Interventions
- First Posted Date
- 2011-10-17
- Last Posted Date
- 2014-02-05
- Lead Sponsor
- Takeda
- Target Recruit Count
- 642
- Registration Number
- NCT01452750
Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose Aspirin
Phase 3
Completed
- Conditions
- Gastric UlcersDuodenal Ulcers
- Interventions
- First Posted Date
- 2011-10-17
- Last Posted Date
- 2014-01-20
- Lead Sponsor
- Takeda
- Target Recruit Count
- 621
- Registration Number
- NCT01452763
A Long-term Extension Study of TAK-385 in the Treatment of Endometriosis
Phase 2
Completed
- Conditions
- Endometriosis
- Interventions
- First Posted Date
- 2011-10-17
- Last Posted Date
- 2014-05-08
- Lead Sponsor
- Takeda
- Target Recruit Count
- 397
- Registration Number
- NCT01452685
Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Erosive Esophagitis
Phase 3
Completed
- Conditions
- Erosive Esophagitis
- Interventions
- First Posted Date
- 2011-10-17
- Last Posted Date
- 2012-11-09
- Lead Sponsor
- Takeda
- Target Recruit Count
- 409
- Registration Number
- NCT01452698
Efficacy and Safety of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Duodenal Ulcer
- First Posted Date
- 2011-10-17
- Last Posted Date
- 2013-08-20
- Lead Sponsor
- Takeda
- Target Recruit Count
- 372
- Registration Number
- NCT01452724
Long-Term Safety Study of TAK-438 in the Maintenance Treatment of Healed Erosive Esophagitis
- First Posted Date
- 2011-10-17
- Last Posted Date
- 2013-11-05
- Lead Sponsor
- Takeda
- Target Recruit Count
- 305
- Registration Number
- NCT01452776
© Copyright 2025. All Rights Reserved by MedPath